The Open, Closed, and Exploding World of Research Data

Data is growing exponentially and so are the associated challenges (i.e., privacy, quality, security, accessibility, etc.). As life science research organizations move away from multiple technology vendors that supply a myriad of infrastructures requiring costly integrations that do not deliver interoperability how can we enhance data quality, increase efficiency, and drive innovation in clinical trials?

Register Free: https://www.pharmexec.com/pe_w/research-data

Event Overview:

Data is growing exponentially and the impact on all areas of academic, scientific, and medical research is critical. Research data challenges can arise from various aspects, including data privacy, quality, security, accessibility, integration, sample size, ethical considerations, resource constraints, and data analysis and interpretation. Adhering to FAIR and CARE principles and updated federal mandates add new layers of complexity. Addressing these challenges requires thoughtful planning, attention to standards, and expertise in research methods and data management to ensure robust and reliable research findings.

This session will explore the intersection of open data, closed data, and discuss the benefits and challenges of open science, ethical and legal considerations related to sharing sensitive research data like PHI, key principles and best practices, and the implications for the future of scientific and life sciences research. As life science research organizations move away from multiple technology vendors that supply a myriad of infrastructures requiring costly integrations that do not deliver interoperability how can we enhance data quality, increase efficiency, and drive innovation in clinical trials?

Key Learning Objectives:

• Differences between open data vs. closed data
• How to implement standards like FAIR and CARE principles.
• How to ensure security, privacy and ethics while having meaningful use.
• The importance of standards.
• Benefits of comprehensive and interoperable platforms to deliver flexibility, ease of use, security, and performance.

Who Should Attend:

This webinar is applicable to:

• Clinical researchers, academic researchers, data scientists, and clinical decision teams responsible for:
  • Research data computing and planning
  • Clinical development planning and study design
  • Management of patients and measurement of clinical outcomes
  • Clinical data management, collecting and evaluating trial metrics
  • Project management of studies, process optimization, and operational excellence

Speakers:

ALLISON DERBENWICK MILLER
VP
Oracle

Alison Derbenwick Miller is the Vice President of Oracle for Research, leading Oracle’s global strategy and development for the research industry. Alison serves on numerous advisory boards and committees, and she was recognized in Business Insider’s Cloudverse 100 list in 2022 and was named as the 2022 STEM Award Winner by Women Worth Watching. Prior to her current role, Alison held leadership positions at Oracle Academy and played a key role in expanding the program globally. She has been recognized for her contributions to initiatives such as "Computer Science for All" and "Let Girls Learn," receiving accolades from President Barack Obama. Alison's diverse background also includes roles at Nuance Communications and Opscentric. She holds bachelor’s degrees in communication and history with Honors from Stanford University, along with a master's degree in Jurisprudence and Social Policy from the University of California at Berkeley.


HILARY HANAHOE
Secretary General
Research Data Alliance

Hilary Hanahoe is the Secretary General of the Research Data Alliance (RDA), a global organization of 13,500+ researchers and innovators focused on enabling open sharing and re-use of data. Hilary’s responsibilities include leadership of RDA’s membership, effective management of the RDA organization and its legal entity (RDA Foundation), engagement with RDA stakeholders and organizations, and sustainable stewardship of the dynamic, active, and high-impact community. Prior to becoming Secretary General, she covered a multiple of roles within the Alliance, including the coordinator of the RDA Europe initiative, the Communications and Plenary Manager for the RDA global secretariat. In recent years, she managed the process for the recognition of RDA recommendations as ICT technical specifications in Europe and has considerable experience in community development and data infrastructures specifically in the delivery and implementation of the user-centric communication platform and communications and outreach strategies.

DR. IMRE BERGER
Founder & CEO
Halo Therapeutics

Dr. Imre Berger is a professor of Biochemistry at the University of Bristol; Director for the Max Planck Bristol Centre for Minimal Biology; and co-founder and chief strategy officer at Halo Therapeutics, a University of Bristol spin-out. Dr. Berger has been published in countless scientific and academic journals, and his work covers multiple areas of biochemistry - from biomolecules to biosystems to in silico design – but his recent work has been focused on coronaviruses, specifically developing pan-coronavirus antivirals at Halo Therapeutics.

JULIE SMILEY
Sr. Director, Life Sciences Product Strategy
Oracle

Julie Smiley is Sr. Director of Life Sciences Product Strategy at Oracle. She has over 20 years of experience in the pharmaceutical industry and holds an MS in Computer Information Systems from Boston University. For most of her career, Julie led data management and database programming organizations and as a solution strategist for Oracle Health Sciences, she continues to lead in driving efficiencies across clinical R&D.

Register Free: https://www.pharmexec.com/pe_w/research-data